---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-24-009785"
form_type: "8-K"
ticker: "ALZN"
cik: "0001677077"
company_name: "Alzamend Neuro, Inc."
filed_at: "2024-05-22T23:59:59+00:00"
generated_at: "2026-06-01T09:46:58.305882+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alzamend Neuro gets Nasdaq extension to meet $2.5M equity rule by Sept 23, 2024

## Summary
- Nasdaq Hearings Panel granted continued listing on Capital Market, subject to compliance with Listing Rule 5550(b)(1).
- Company must demonstrate stockholder equity of at least $2.5 million on or before September 23, 2024.
- Appeal hearing held May 9, 2024; panel decision received May 21, 2024.
- CEO Stephan Jackman stated company is implementing its compliance plan.

## SEC filing metadata
- accession: 0001214659-24-009785
- form_type: 8-K
- ticker: ALZN
- cik: 0001677077
- company_name: Alzamend Neuro, Inc.
- filed_at: 2024-05-22T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465924009785/0001214659-24-009785-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677077/000121465924009785/p5212408k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-24-009785
- JSON: https://secwatch.observer/filing/0001214659-24-009785.json
- Plain text: https://secwatch.observer/filing/0001214659-24-009785.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.